| Purity: | 99% |
|---|---|
| Type: | Auxiliaries and Other Medicinal Chemicals |
| Place of Origin: | China (Mainland) |
| CAS No.: | 540737-29-9 |
Quick Details
Specifications
TOFACITINIB CITRATE
CAS 540737-29-9
Unstable oil
Assay: 99%
Chemical name:
(3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate
By name: CP-690550
Description
Tofacitinib, an inhibitor of Janus kinases (JAKs), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Tofacitinib should not be used in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.
CAS 540737-29-9
Unstable oil
Assay: 99%
Chemical name:
(3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate
By name: CP-690550
Description
Tofacitinib, an inhibitor of Janus kinases (JAKs), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Tofacitinib should not be used in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.